363 related articles for article (PubMed ID: 26659482)
1. Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.
Sivakumaran S; Maguire J
Epilepsia; 2016 Feb; 57(2):222-32. PubMed ID: 26659482
[TBL] [Abstract][Full Text] [Related]
2. Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis.
Dzhala V; Staley KJ
CNS Neurosci Ther; 2015 Feb; 21(2):173-80. PubMed ID: 25495911
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Auer T; Schreppel P; Erker T; Schwarzer C
Neuropharmacology; 2020 Jan; 162():107754. PubMed ID: 31476353
[TBL] [Abstract][Full Text] [Related]
4. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
Dzhala VI; Brumback AC; Staley KJ
Ann Neurol; 2008 Feb; 63(2):222-35. PubMed ID: 17918265
[TBL] [Abstract][Full Text] [Related]
5. NKCC1 transporter facilitates seizures in the developing brain.
Dzhala VI; Talos DM; Sdrulla DA; Brumback AC; Mathews GC; Benke TA; Delpire E; Jensen FE; Staley KJ
Nat Med; 2005 Nov; 11(11):1205-13. PubMed ID: 16227993
[TBL] [Abstract][Full Text] [Related]
6. Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus.
Nardou R; Ben-Ari Y; Khalilov I
J Neurophysiol; 2009 Jun; 101(6):2878-88. PubMed ID: 19297515
[TBL] [Abstract][Full Text] [Related]
7. Long-duration self-sustained epileptiform activity in the hippocampal-parahippocampal slice: a model of status epilepticus.
Rafiq A; Zhang YF; DeLorenzo RJ; Coulter DA
J Neurophysiol; 1995 Nov; 74(5):2028-42. PubMed ID: 8592194
[TBL] [Abstract][Full Text] [Related]
8. Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus.
Barmashenko G; Hefft S; Aertsen A; Kirschstein T; Köhling R
Epilepsia; 2011 Sep; 52(9):1570-8. PubMed ID: 21899534
[TBL] [Abstract][Full Text] [Related]
9. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
10. Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs.
West PJ; Saunders GW; Billingsley P; Smith MD; White HS; Metcalf CS; Wilcox KS
Epilepsia; 2018 Nov; 59(11):2035-2048. PubMed ID: 30328622
[TBL] [Abstract][Full Text] [Related]
11. Age- and region-specific effects of anticonvulsants and bumetanide on 4-aminopyridine-induced seizure-like events in immature rat hippocampal-entorhinal cortex slices.
Wahab A; Albus K; Heinemann U
Epilepsia; 2011 Jan; 52(1):94-103. PubMed ID: 21083847
[TBL] [Abstract][Full Text] [Related]
12. Phosphatase inhibition prevents the activity-dependent trafficking of GABAA receptors during status epilepticus in the young animal.
Joshi S; Rajasekaran K; Hawk KM; Brar J; Ross BM; Tran CA; Chester SJ; Goodkin HP
Epilepsia; 2015 Sep; 56(9):1355-65. PubMed ID: 26248944
[TBL] [Abstract][Full Text] [Related]
13. Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models.
Töllner K; Brandt C; Erker T; Löscher W
Eur J Pharmacol; 2015 Jan; 746():78-88. PubMed ID: 25445051
[TBL] [Abstract][Full Text] [Related]
14. Astrocytic NKCC1 inhibits seizures by buffering Cl
Nguyen TD; Ishibashi M; Sinha AS; Watanabe M; Kato D; Horiuchi H; Wake H; Fukuda A
Epilepsia; 2023 Dec; 64(12):3389-3403. PubMed ID: 37779224
[TBL] [Abstract][Full Text] [Related]
15. Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus.
Burman RJ; Selfe JS; Lee JH; van den Berg M; Calin A; Codadu NK; Wright R; Newey SE; Parrish RR; Katz AA; Wilmshurst JM; Akerman CJ; Trevelyan AJ; Raimondo JV
Brain; 2019 Nov; 142(11):3482-3501. PubMed ID: 31553050
[TBL] [Abstract][Full Text] [Related]
16. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1.
Kahle KT; Barnett SM; Sassower KC; Staley KJ
J Child Neurol; 2009 May; 24(5):572-6. PubMed ID: 19406757
[TBL] [Abstract][Full Text] [Related]
17. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy.
Töpfer M; Töllner K; Brandt C; Twele F; Bröer S; Löscher W
Eur J Neurosci; 2014 Feb; 39(4):673-87. PubMed ID: 24251546
[TBL] [Abstract][Full Text] [Related]
18. Hyponatremia augments kainic-acid induced status epilepticus in the mouse: a model for dysmetabolic status epilepticus.
Zelano J; Halawa I; Clausen F; Kumlien E
Epilepsy Res; 2013 Sep; 106(1-2):29-34. PubMed ID: 23790965
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures.
Wang S; Zhang XQ; Song CG; Xiao T; Zhao M; Zhu G; Zhao CS
Neuroscience; 2015 Feb; 286():203-15. PubMed ID: 25463517
[TBL] [Abstract][Full Text] [Related]
20. Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility.
MacKenzie G; Maguire J
Epilepsy Res; 2015 Jan; 109():13-27. PubMed ID: 25524838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
